Short Term Aggressive Call

Buy Sumedha (BSE - 530419) at CMP of 28.5 - 29
Add till 26
SL 25
Targets:- 30 - 30.7 - 31.4 - 32 - 33+
Time Frame :- Max 5 - 8 days

Disclaimer;- I am not SEBI Registered. Please consult your financial advisor before investing

Sumedha 31 ❤️

Zooming ✈️✈️✈️

Sumedha 31.75 ❤️

Going towards UC levels 💸💸

FSC 75.75 ❤️

Upper Circuit locked 🔒

Mid Term Aggressive Call

Buy KKCL at CMP of 907 - 915 and dips till 800
Sl 790
Trading SL - 850
Targets:- Upto 930 - 938 - 950+
Above 950 we can see 1000 - 1100 - 1200 +

Disclaimer:- I am not SEBI Registered. Please consult your financial advisor before investing.

GPT INFRA 53.4❤️❤️

GPT INFRA 54.5❤️❤️

KKCL 975 ❤️

Zooming ✈️✈️😜

KKCL Short Term targets done in 10 mins 😂😜

GPT INFRA 57❤️❤️

Mid or Long Term Quality Fundamental Call

Buy Triton Valves (Bse - 505978) at CMP of 1014 - 1025 and dips till 900
Sl 862
Targets:- 1050 - 1074 - 1104 - 1177 - 1250+
Above that we can see 1350 - 1500+

Disclaimer:- I am not SEBI Registered. Please consult your financial advisor before investing.

TOKYO PLAST 97.5❤️❤️❤️

Techno Funda Short Term Call

Buy HIMTEK (BSE - 505712) at CMP of 94.5 - 96 and dips till 89
Sl 84
Targets:- 100 - 102 - 104 - 107 - 110 - 113 - 117 - 120+

Disclaimer:- I am not SEBI Registered. Please consult your financial advisor before investing.

Himtek 97.5 ❤️

Tokyo plast 103❤️❤️❤️❤️

SIGIND - 20%
INDOBORAX - 20%
INTENSE TECH - 20%
GOKUL AGRO - 20%
PDSML - 20%
TTK HEALTHCARE - 18%
TOKYO PLAST - 18%
NSIL - 13%
SUMEDHA - 18%
GPT INFRA 18%
SHREYAS SHIPPING - 10%
WHITE ORGANICS -10%
TIDE WATER - 10%
DCM - 10%
NDGL - 10%
KKCL - 12%
TRITON - 13%

STOCKS WHICH ARE UP MORE THAN 10%. 🔥🔥

POWER OF MARKET WIZARD RESEARCH. STOCKS WHICH ARE UP BUT LESS THAN 10% IS NOT INCLUDED HERE IN THIS LIST.

Follow this link to join my WhatsApp group: https://chat.whatsapp.com/KUuI70RifSW7chXFiwwAMY

The Phase-3 of SEBI’s new margin framework is being implemented w.e.f. 1st June 2021. As a result, the Intraday leverage is revised to 6.6x (Max.) for Equity and 1.33x for Futures & Options (Selling)
#intraday #margin

SHILPA MEDICARE: Q4 EBITDA RUPEES 262M VS 456M (YOY) | 210M (QOQ) || Q4 EBITDA MARGIN 12.6% VS 20.73% (YOY) | 10.96% (QOQ)

*Aurobindo Pharma Q4 First Cut – Ebitda and Ebitda margin ahead of expectation*

Q4 net profit Rs802cr (down 7.2% YoY) – expectation Rs732cr

Ebitda margin 21.2% VS 21.4% (YoY) – expectation 20.7%

Ebitda Rs1274.6cr (down 3.2% YoY) – expectation Rs1251cr

Income Rs6000cr (down 2.5% YoY) – expectation Rs6029.6cr

*31-May: Prov Cash: Rs.crs*
*FIIs: +2412.39* (7456.51-5044.12)
*DIIs: +179.78* (4912.06-4732.28)